Introduction
Influenza vaccines in current use require annual updating in vaccination, with either T cell subset alone sufficient to promote survival and recovery. order to induce antibody responses specific for prevalent viral strains. A vaccine relying on conserved viral epitopes might induce responses active against a broad range of Methods influenza viruses. Broadly reactive responses could improve protection in years when the vaccine does not match circulatPlasmids ing strains, perhaps even against unexpected pandemic strains.
The plasmid VR1012 was obtained from Vical (San Diego, CA) In efforts to induce immunity to conserved influenza antiunder a Materials Transfer Agreement. Full-length influenza gens, much attention has focussed on induction of CD8 ϩ genes were prepared and inserted into VR1012 as follows. cytotoxic T lymphocyte (CTL) responses by multiple antigens Restriction enzyme cleavage sites are indicated by italics in humans (1) and by nucleoprotein (NP) in the mouse (2), and arrows. although mice do make CTL responses specific for multiple pA/NP. The influenza A/PR/8/34 NP gene was subcloned other influenza antigens (3). Similarly, CTL responses have by PCR from the vector CMV-Int-PRNP obtained from Dr also been the subject of intense study in vaccine development Suezanne Parker, Vical, under a Materials Transfer efforts for HIV (4,5), because anti-HIV neutralizing antibodies Agreement. Primers were synthesized with the following are often too narrow in strain specificity to protect against the sequences: forward primer 5Ј-gcg cgc g↓tc gac agc aaa range of viral variants. In influenza, CD8 ϩ CTL are prominent agc agg gta gat-3Ј (SalI site indicated) and reverse primer in the infected lungs (6) and clearly play an important role in 5Ј-cgc gcg t↓ct aga agt aga aac aag ggt att-3Ј (XbaI site clearance of existing infection (7-11). Plasmid DNA and indicated). resulting endogenous antigen expression could induce pA/M. The influenza A/PR/8/34 matrix gene was subcloned immune responses without the risks of live virus exposure, from pT3PR8M (a gift from Yoshihiro Kawaoka, St Jude and perhaps maintain CTL activity for longer periods than Children's Research Hospital, Memphis, TN) by PCR. The does a viral infection which is rapidly cleared. However, a insert contained the full-length M gene segment with both the realistic assessment of these potential advantages or of the M1 and M2 open reading frames and flanking non-coding possible economic and logistic advantages of DNA vaccines regions. Primers were designed as follows: forward primer has not been made.
5Ј-gcg cgc t↓ct aga agc gaa agc agg tag ata-3Ј (XbaI site When DNA vaccines for influenza were first studied, a indicated) and reverse primer 5Ј-cgc gcg a↓ga tct agt aga construct expressing NP was shown to induce both antibody aac aag gta gtt-3Ј (BglII site indicated). The nucleotide sequences of the inserts were confirmed and CTL responses, as well as protection against lethal and bulk preparations of plasmid DNA were prepared by challenge (18) . Another report confirmed these findings and BioServe (Laurel, MD) by fermentation in Escherichia coli and suggested that the mechanism of protection was likely CD8 ϩ , two rounds of CsCl purification. Quality control testing by MHC class I-restricted CTL (19) . However, while such CTL restriction digestion and agarose gel electrophoresis conwere induced, their role in protection was not initially firmed plasmid size and purity. All plasmid lots were tested evaluated. Further studies of DNA vaccination to influenza for endotoxin levels by CBER's Division of Product Quality have used hemagglutinin (HA) as well as genes for internal Control using the chromogenic LAL assay, in order to avoid components and have analyzed antibody as well as T cell non-specific polyclonal effects in vivo. Endotoxin levels were immunity (20) (21) (22) (23) (24) . Regarding protection by conserved internal Ͻ1 EU/100 µg dose. components, a study using NP DNA vaccination reported that depletion of CD8 ϩ cells just prior to challenge abrogated Viruses protection against lethal challenge completely, while depletion of CD4 ϩ cells had a partial effect (25) .
Influenza virus strains used were A/PR/8/34 (H1N1) Successful development and use of new vaccines will be obtained from Dr Jonathan Yewdell, (NIAID, NIH, Bethesda, aided if their mechanisms of action are understood. We tested MD), A/Udorn/307/72 (H3N2) and B/Ann Arbor/1/86 the roles of T cell subsets in protective immunity induced obtained from Dr Brian Murphy (NIAID, NIH, Bethesda, MD), by DNA vaccination, using constructs encoding conserved and A/Philippines/2/82/X-79 (A/Phil; H3N2) described previinternal proteins (NP and M) of influenza virus and a lethal ously (26) and obtained from Dr Roland Levandowski (CBER, challenge model. The mice immunized had defined, partial FDA, Bethesda, MD). A/Phil is a reassortant virus (27) with immune deficiencies, due either to targeted disruption of the the HA and NA genes of A/Philippines/2/82 origin, and the β 2 -microglobulin (β 2 m) gene or to acute in vivo depletion of NP and M genes of A/PR/8/34 origin (28). Thus it is not one or more T cell subsets during the challenge period. Since fully heterosubtypic compared to A/PR/8 in that genes for lymphocytes in the lungs may be particularly relevant to multiple internal components are shared, but it lacks shared virus clearance, we focussed attention on them. Lymphocyte external antigens reactive with neutralizing antibody. The subpopulations in the infected lungs were monitored by stock of A/Phil used in vivo was prepared as a pooled flow cytometry and CTL activity was assayed in fresh lung homogenate of lungs from mice infected 4 days previously. lymphocytes without re-stimulation. Outcomes in our chalOther influenza viruses were prepared in the allantoic cavities lenge experiments showed balanced contributions of the of 9-to 10-day-old embryonated hen's eggs. Virus stocks were frozen at -70°C until use. CD4 ϩ or the CD8 ϩ subsets to protection by NP ϩ M DNA The mAb used for in vivo depletion were: GK1.5 specific for mouse CD4 (31), 2.43 specific for mouse CD8 (32), SFR3-Mice DR5 specific for human leukocyte antigen, used as a negative BALB/c and C57BL/6 (B6) female mice were purchased from control, and 30-H12 specific for mouse CD90, previously the Division of Cancer Treatment, National Cancer Institute.
called Thy-1.2 (33), a clone that does not activate T cells B6-β 2 m(-/-) mice of both sexes were obtained and bred in (34) . Ascites fluid was prepared by Harlan Bioproducts for our colony as described previously (28) . Protocols for in vivo Science (Madison, WI). All mAb are rat IgG2b antibodies and experiments were approved by the CBER Animal Care and were used as delipified ascites. The concentration of rat Use Committee. The name β 2 m(-/-) mice used in the text IgG2b was measured by radial immunodiffusion, using kits includes β 2 m knockout mice on other genetic backgrounds from The Binding Site (Birmingham, UK), and all doses were used in other studies.
1 mg/mouse of each antibody. The acute depletion protocol has been reported previously (28) . Plasmid immunizations DNA was injected i.m. in the quadriceps of mice, with the Flow cytometry injected volume divided equally between the two legs. Pilot
Flow cytometry was used to confirm completeness of in vivo experiments comparing doses and intervals established the T cell depletion within each experiment. Spleen, lung and immunization protocol of three 100 µg doses of each plasmid, lymph node cell suspensions were prepared by mincing the given i.m. 2 weeks apart. Mice were immunized starting at tissue, straining through nylon mesh, and lysing red blood 6-7 weeks of age because responses were weaker and more cells with ammonium chloride-potassium buffer. Singlevariable in older mice (data not shown). Two weeks after the color analysis utilized the stains and procedures described final DNA injection, mice were challenged with live influenza previously (28) , except that cells were fixed with 1% paraformvirus intranasally (i.n.) under Metofane anesthesia. They were aldehyde (Sigma, St Louis, MO) in PBS for at least 30 min. monitored for body wt and mortality until survivors were Also, in some cases apoptotic cells were excluded by staining regaining weight (at least 2 weeks) or were sacrificed for with 7-amino-actinomycin D (Sigma) (35). In early experiin vitro virus titration of lung homogenates. Differences in ments, single-color flow cytometry analyses of spleen cells survival were compared by Fisher's exact test using SigmaPlot showed that simultaneous depletion of CD4 ϩ and CD8 ϩ T software from SPSS. Differences in survival kinetics were cells left some cells staining for CD90. Addition of anti-CD90 subjected to Kaplan-Meier statistical comparisons using the to the depletion mixture reduced numbers of CD90 ϩ cells to JMP program from SAS Institute, Inc.
very low levels, but did not appear to further reduce the In preliminary studies, vaccine-induced defense against numbers of CD4 ϩ cells (data not shown). lethal challenge was not improved by use of sucrose or
In order to assess only T cells, two-color analyses were bupivacaine as diluents compared to saline (data not shown), performed with staining for CD3 versus CD4, CD8 or CD90. so low-endotoxin saline or PBS was used in further studies, Cells were preincubated with DNase I (Sigma) at 0.01 mg/ml with comparable in vivo results. Vaccine-induced protection for 5 min at room temperature. Staining used phycoerythrin could be overwhelmed by higher challenge doses (data not (PE) conjugated anti-mouse CD3ε ('anti-mouse CD3e'; shown), so the dose chosen was the lowest dose lethal to PharMingen, San Diego, CA) along with FITC-conjugated antimost unimmunized mice, consistent with the use of LD 90 T cell antibodies as follows: anti-mouse L3T4 (CD4), RM4.4 challenge by Rhodes et al. (18) . The challenge viruses were (CD4) and anti-mouse Ly3.2 (CD8b.2) (all from PharMingen); titrated in vivo in each mouse strain, because susceptibility anti-mouse Thy1.2 (CD90), anti-mouse Lyt 2 (CD8a) and antidiffers. A challenge dose of 10 4 TCID 50 /mouse of A/Phil was human Leu2a as a negative control (all from Collaborative chosen for B6 mice, while 1-2ϫ10 3 TCID 50 /mouse was chosen Biomedical Products, Bedford, MA). PE and FITC stains were for BALB/c mice.
added to the cells in the presence of 2.4G2, a rat mAb to the mouse Fc receptor derived and generously distributed by Dr ELISA for antibodies to influenza NP Jay Unkeless (36), a gift of Dr Elizabeth Shores (CBER, FDA, Antibodies to NP were assayed on plates coated with extracts Bethesda, MD) (37) . In some experiments, aliquots of cells of HeLa cells infected with NP-VAC, as described previously were stained with FITC-anti-rat Ig absorbed against mouse (28) . The cells were harvested, subjected to three cycles of serum proteins (Southern Biotechnology Associates, freezing-thawing and then spun down at 1250 g. Control Birmingham, AL) to detect any residual cells that might have extracts were made from HeLa cells infected with a vaccinia been coated with the injected mAb but not deleted. No construct expressing the HN protein of parainfluenza virus.
staining above background was seen with anti-rat Ig, while Plates coated with this extract showed no antibody activity in this reagent stained strongly cells intentionally coated with NP or NP ϩ M immunized mice.
GK1.5 as a control (data not shown 
Vaccination with DNA expressing influenza virus proteins
As shown in Fig. 1(A) , B6 mice immunized with NP ϩ M Mice were immunized with plasmids i.m., using a schedule, DNA recovered from a challenge that was lethal to mice given DNA dose and diluent established in preliminary experiments.
control DNA lacking an insert. In contrast (Fig. 1B) , B6-β 2 m(-/-) mice immunized with NP ϩ M DNA succumbed to Immunization used DNA expressing NP and in most cases M as indicated or plasmid VR1012 without an insert to control challenge infection. This result might suggest that class I-restricted CTL are needed for vaccine-induced promotion for non-specific immune stimulation due to CpG motifs (39), of which there are a number in the plasmid backbone. Note of recovery. However, further analysis of immune responses in B6-β 2 m(-/-) mice shows that one cannot draw that conclusion that the H-2 b (B6) and H-2 d (BALB/c) haplotypes are both responders to NP (40) , and both strains made antibodies to (following and Discussion). Immunization of B6 mice with NP plasmid caused only a protective upon passive transfer (19), we analyzed them in order to assess whether the antibody response defect in modest reduction in challenge virus replication compared to controls (Table 1) at day 4 post-challenge, chosen as being β 2 m(-/-) mice extended to DNA vaccination. Serum IgG1 and IgG2a antibody responses to NP in sera of the around the peak of virus replication in the lungs. This result is consistent with the previous studies of purified NP protein immunized mice were analyzed by ELISA. As shown in Fig. 2 , anti-NP titers of the IgG2a isotype induced by DNA or NP-expressing vaccinia recombinants cited above. In BALB/c mice, lung virus titers were again reduced only vaccination were significantly higher in B6 mice than in B6-β 2 m(-/-) mice (P ϭ 0.0014, Student's t-test). IgG1 titers were partially after immunization with a mixture of both NP and M constructs (Table 1) with NP ϩ M DNA survived challenge that was lethal to naive mice or to mice given control DNA. Unexpectedly, depletion of CD8 ϩ cells during the challenge period had only an insignificant effect on survival, compared to controls. This indicates that CD8 ϩ CTL were not solely responsible for survival and furthermore that they were not even necessary. Similarly, depletion of CD4 ϩ cells did not affect survival significantly. Mice depleted of both CD4 ϩ and CD8 ϩ T cells, with or without additional depletion by anti-CD90, did not survive, indicating that effector T cells of these two subsets account for the immune defense against disease. In one experiment, CD4,CD8,CD90-depleted mice died~3 days earlier than CD4,CD8-depleted mice, but this was not signi- 
Phenotypic analysis of T cell-depleted mice test). The kinetic difference seen in the B6-β 2 m(-/-) mice (NP ϩ
Effectiveness of the T cell depletion procedure was examined M immunized mice dying faster than controls) was not reproduced in a another experiment.
by flow cytometry. In addition to spleens, lymphocytes isolated from infected lungs were analyzed, since this population is particularly relevant to viral clearance. To maximize detection, analyses were performed at the height of the response after
Acute T cell depletion for analysis of immune effector phase: viral challenge, when any residual T cells could have been role of T cells in promoting recovery
re-expanded. Counter-staining with anti-CD3 assured that only T cells were analyzed. Given the limitations on interpretation of experiments in β 2 m knockout mice, we turned to acute depletion of T cells to As shown in Fig. 4 , CD4 depletion alone or CD8 depletion alone left very few residual T cells of the respective subset analyze their contributions to survival and recovery. After vaccination with NP ϩ M plasmid DNA, T cell subsets were in the lungs. Depletion of both T cell subsets by injection of a mixture of anti-CD4 and anti-CD8 also left very few residual depleted in immunocompetent mice during the challenge period. As shown in Fig. 3 , intact BALB/c mice vaccinated cells of the corresponding phenotypes, but some double-in lungs and spleen, was incomplete in lymph nodes, with 10% of residual cells staining brightly for CD90 in the cervical lymph node and 15% in the mediastinal lymph node after CD4,CD8,CD90 depletion in vivo.
Functional depletion: CTL activity
The effectiveness of T cell depletion in eliminating CTL activity was analyzed in DNA vaccinated mice, as it has been in previous studies of mice immunized with live virus (38,50). We measured MHC class I-restricted CTL activity at the height of the in vivo recall response 7 days after challenge, without in vitro re-stimulation. As expected, both A/PR/8-and A/Phil-infected targets were lysed by lung CTL, since the NP and M genes of the two viruses are the same (Fig. 5) . Very strong CTL activity was seen in the lungs of immunized and challenged mice not depleted of any T cells, with some CTL activity seen even at E:T ratios of 1:1. Lytic capacity on targets infected with either A/PR/8 or A/Phil was reduced at least 64-fold by CD8-depletion, compared to control mice not depleted of T cells. The modest CTL activity seen in the spleens (data not shown) was specific for influenza A-infected targets and was completely absent in CD8-depleted mice. In a separate depletion experiment, CTL activity in lung cells of CD8-or CD4,CD8-depleted mice was also drastically reduced (~32-fold reduction in lytic units; data not shown). Thus, cytolytic activity was abrogated in mice depleted of CD8 ϩ T cells, time of challenge and CTL reactivation. A small difference in Each experiment gave comparable results for the depletions included, with one exception: in one experiment but not a second one, CTL activity is shown in Fig. 5 between mice subject to CD8 CD4,CD8,CD90-depleted mice died~3 days earlier than CD4,CD8-depletion alone and to CD4,CD8 depletion. However, part of depleted mice. Significance of differences between groups by the minor lytic activity in the CD8-depleted mice was also Fisher's exact test: effect of CD4 depletion not significant (P Ͼ 0.3 seen on uninfected targets or flu B-infected targets and is versus control mAb SFR3-DR5); effect of CD8 depletion not significant thus non-specific, and was reduced in CD4,CD8-depleted (P Ͼ 0.2 versus SFR3-DR5); effect of CD4,CD8 depletion highly significant (P Ͻ 0.001 versus SFR3-DR5); effect of CD4,CD8,CD90 mice (data not shown).
depletion highly significant (P Ͻ 0.001 versus SFR3-DR5).
Discussion
Vaccination with DNA encoding internal proteins from an negative, CD90 ϩ cells remained. Depletion of all T cells by treatment with anti-CD4, anti-CD8 and anti-CD90 further influenza A virus of the H1N1 subtype protected mice against lethal challenge with a virus of the H3N2 subtype, as has reduced the number of residual CD90 ϩ cells. Multiple mice of each depletion type were analyzed and there was some been reported by other investigators (19) . However, such immune defense against challenge viruses that belong to variation between individual mice, with 3.6% CD4 ϩ cells remaining in one anti-CD4-treated mouse and 3.4% CD8 ϩ different subtypes, termed heterosubtypic immunity, is also observed in animals following immunization with live virus and cells in one anti-CD8-treated mouse. However, the few cells that were scored as positive displayed staining only marginally is not a novel property of DNA vaccines. A long literature beginning in the 1960s reports and analyzes such findings above that of negative staining controls (Fig. 4) .
T cells in the lymph nodes might also be relevant to immune in mice and ferrets (28,41,50-52), using widely divergent virus strains. Heterosubtypic immunity has occasionally been responses to virus. Cells from mediastinal and cervical lymph nodes, as well as lungs and spleen, were analyzed in one reported in humans (53, 54), but its potency and duration are limited. It remains to be seen if DNA vaccines will be more experiment. Staining of these cells demonstrated depletion of CD4 ϩ or CD8 ϩ T cells comparable to or better than that successful at inducing broad cross-protection in humans than is live virus or if once again cross-protection will be more for lungs (data not shown). CD90 depletion, while complete Acute T cell depletion in normal mice during the challenge period provided an alternative approach. Depletion of either CD4 ϩ or CD8 ϩ T cells had only insignificant effects on survival. Simultaneous depletion of both CD4 ϩ and CD8 ϩ T cells with or without addition of anti-CD90, however, dramatically reduced survival. This suggests that function by either CD4 ϩ or CD8 ϩ T cells can suffice for immune defense against challenge infection. It should be noted that CD8 ϩ T cell responses can enhance survival by clearing virus, but they can also produce immunopathological damage to the lungs. The competing contributions of these two effects were studied in detail in BALB/c versus nude mice by Wells et al. (63) . BALB/c mice succumbed early or else cleared the virus and survived long term, while nude mice survived the early period, presumably because they were not subject to tissue damage by T cells, but could not clear virus and eventually had higher overall mortality.
A study by Ulmer et al. of DNA vaccination to influenza showed complete abrogation of protective immunity by CD8 depletion and partial abrogation by CD4 depletion (25) . We saw little effect of either depletion alone and saw substantial abrogation of immune defense only when both subsets were depleted. The difference in the two studies is interesting because the experimental conditions were similar in many ways (BALB/c mice, plasmids constructed with NP genes from A/PR/8, H3N2 virus challenge, similar DNA doses and immunization schedule, and in vivo CD8 depletion with a mAb specific for CD8a). Differences in effectiveness of in vivo depletion do not seem to explain the outcomes. Our analysis showing only very low numbers of residual CD8 ϩ cells after depletion was more rigorous, in that we stained lung lymphocytes at the height of challenge infection when residual cells and observed depletion of activity.
Possible explanations for the differing outcomes include the difference in challenge dose (50% lethality in the Ulmer study, 100% in ours), the specific challenge virus strains β 2 m(-/-) mice display cytolytic activity to influenza antigens only on class II ϩ targets and this activity is due to CD4 ϩ , (A/HK/68 in the Ulmer study, A/Phil in ours) and our use of M in addition to NP DNA. We are further analyzing effector not CD8 ϩ , cells (61) .
Under the conditions studied, B6-β 2 m(-/-) mice were not mechanisms induced by M DNA to address one of these possibilities. Previous studies have shown that T cells specific protected against lethal virus challenge by NP ϩ M DNA vaccination. While this result suggests a requirement for for M can provide potent help (64), and our M plasmid given alone promotes survival and recovery (Benton et al., CTL in survival, alternative explanations are possible due to defects in other immune compartments. We found that unpublished data). Regarding the challenge virus strains, A/Phil is a reassortant H3N2 virus with genes for internal viral DNA vaccination elicited lower NP-specific antibody titers in these mice than in normal mice, as previously reported for proteins derived from A/PR/8. A/HK/68 is not a reassortant and so the A/PR/8 NP gene in the DNA vaccine differs from viral and protein antigens (43, 46, 48 protective immunity has been emphasized in interpreting to some other pathogens (72, 73) . CD4 ϩ T cells also appear
